Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mercury-197m (Hg-197m) is a cyclotron-produced, theranostic radionuclide with a half-life of approximately 23.8 hours. It decays via electron capture and isomeric transition to mercury-197 (Hg-197), emitting low-energy gamma rays suitable for single-photon emission computed tomography (SPECT) imaging, alongside a cascade of conversion and Auger electrons. These high-LET (linear energy transfer) Auger electrons deposit highly localized, cytotoxic radiation within a short range (nanometer to micrometer scale), making Hg-197m highly effective for targeted radionuclide therapy of micrometastases and small tumors while minimizing damage to surrounding healthy tissue. Preclinical research focuses on chelating Hg-197m with sulfur-rich macrocycles to conjugate it to tumor-targeting vectors such as monoclonal antibodies (e.g., panitumumab, trastuzumab) or nanoparticles for cancer theranostics.
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | Preclinical | Active |
| glioblastoma, IDH-wildtype | Preclinical | Active |
| prostate cancer and precursor lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mercury-197m.
Work on mercury-197m? Claim this page to correct or add information. Claim this page